![Kamran Alam](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Kamran Alam
Financieel Directeur/CFO bij
TAYSHA GENE THERAPIES, INC.
Vermogen: 8 M $ op 31-05-2026
Profiel
Kamran Alam is currently Chief Financial Officer & Secretary at Taysha Gene Therapies, Inc. since 2020.
Former positions include Chief Financial Officer & Senior Vice President at Rocket Pharmaceuticals, Inc. from 2019 to 2020, Vice President-Finance at Novartis Gene Therapies, Inc. from 2016 to 2019, Senior Director-Finance & Accounting at Aptinyx, Inc. from 2013 to 2016, and Finance Director at Naurex, Inc. Education includes an undergraduate degree from Stephen M.
Ross School of Business and an MBA from Kelley School of Business.
Bekende belangen in openbare bedrijven
| Onderneming | Datum | Aantal aandelen | Totale waarde | Waarderingsdatum |
|---|---|---|---|---|
| 31-03-2026 | 1.341.600 ( 0,49% ) | 8 M $ | 31-05-2026 |
Actieve functies van Kamran Alam
| Bedrijven | Functie | Begin |
|---|---|---|
| TAYSHA GENE THERAPIES, INC. | Financieel Directeur/CFO | 01-08-2020 |
Eerdere bekende functies van Kamran Alam
| Bedrijven | Functie | Einde |
|---|---|---|
| ROCKET PHARMACEUTICALS, INC. | Financieel Directeur/CFO | 01-07-2020 |
| AVEXIS INC | Corporate Officer/Principal | 01-10-2019 |
| APTINYX | Comptroller/Controller/Auditor | 01-04-2016 |
Naurex, Inc.
 Naurex, Inc. Pharmaceuticals: MajorHealth Technology Operates as a clinical-stage company, which develops novel therapies | Corporate Officer/Principal | - |
Opleiding van Kamran Alam
Ervaring
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Connecties
22
Eerstegraads connecties
7
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
Verwante bedrijven
| Bedrijven in privébezit | 7 |
|---|---|
Naurex, Inc.
Naurex, Inc. Pharmaceuticals: MajorHealth Technology Operates as a clinical-stage company, which develops novel therapies | Health Technology |
Stephen M. Ross School of Business
 Stephen M. Ross School of Business Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Kelley School of Business
 Kelley School of Business Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Novartis Gene Therapies, Inc.
 Novartis Gene Therapies, Inc. BiotechnologyHealth Technology Operates as a clinical-stage gene therapy company | Health Technology |
Aptinyx, Inc.
 Aptinyx, Inc. Pharmaceuticals: MajorHealth Technology Operates as a biopharmaceutical company that develops therapies to treat disorders of the brain and nervous system | Health Technology |
Rocket Pharmaceuticals, Inc.
 Rocket Pharmaceuticals, Inc. BiotechnologyHealth Technology Provides gene therapy services | Health Technology |
Taysha Gene Therapies, Inc.
 Taysha Gene Therapies, Inc. BiotechnologyHealth Technology Develops and commercializes adeno-associated viruses-based gene therapies for the treatment of monogenic diseases of the central nervous system | Health Technology |
